// App-Quantinova.ai

P4-22-07 : Long-term safety of palbociclib in combination with endocrine therapy in treatment-naive and previously treated women with HR+ HER2 advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies

Researchers

Presenter

  • V Diéras

Principal Investigators

  • HS Rugo

  • K Gelmon

  • RS Finn

  • M Cristofanilli

  • S Loi

  • M Colleoni

  • D Lu

  • E Gauthier

  • C Huang-Bartlett

  • NC Turner

  • P Schnell

Medical Centers

  • Istituto Europeo di Oncologia, Milano, Italy

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Institut Curie, Paris Cedex, France

  • Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL

  • UCLA David Geffen School of Medicine, Los Angeles, CA

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

Locations

  • Canada

  • Italy

  • United Kingdom

  • Australia

  • United States

  • France

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Breast cancer

  • Neutropenia

  • Solid malignancies

  • Anemia

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Fulvestrant

  • Palbociclib

  • Letrozole

Outcome

  • N/A

Study Design

  • open label

  • randomized

  • double blind/blinded

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved